China's medical products administrator approved Lisheng Pharmaceutical's (SHE:002393) active pharmaceutical ingredient listing for apremilast, according to a Friday filing with the Shenzhen Stock Exchange.
Apremilast is a medication for the treatment of patients with moderate to severe plaque psoriasis who are eligible for phototherapy of systemic treatment, the filing said.
Shares closed 2% during Friday's trading.
Price (RMB): ¥17.07, Change: ¥+0.32, Percent Change: +1.91%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments